文献速递免疫规划妇幼与学校卫生

健康婴儿中2+1剂次V114肺炎球菌疫苗与PCV13的安全性、耐受性和免疫原性比较:III期研究(PNEU-PED-EU-2)

Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
PubMed 文献 · Vaccine · 2023-02-24

这项III期研究将1191名健康婴儿随机分配至V114组(n=595)或PCV13组(n=596),在3、5、12月龄接种2剂基础免疫加1剂幼儿加强免疫,并同时接种DTaP-IPV-Hib-HepB疫苗。V114对13个共有血清型达到非劣效标准,对22F和33F血清型达到优效标准,两组 solicited AE 和 serious AE 比例相当。

要点

  • V114对13个共有血清型免疫应答非劣效于PCV13。
  • V114对额外血清型22F和33F免疫应答优于PCV13。
  • 两组 solicited AE 和 serious AE 比例相当,V114耐受性良好。

核心结论

  • 两剂基础免疫加一剂幼儿加强免疫的V114在健康婴儿中耐受性良好,对13个共有血清型免疫应答非劣效于PCV13,对额外血清型22F和33F免疫应答优于PCV13。

研究设计与样本

  • III期研究,健康婴儿随机接受2剂基础免疫和1剂幼儿加强免疫(2+1方案)的V114或PCV13,在3、5、12月龄接种,同时接种DTaP-IPV-Hib-HepB疫苗。
  • 1191名健康婴儿随机分配至V114组(n=595)或PCV13组(n=596)。

主要发现

  • V114组和PCV13组发生 solicited AE 和 serious AE 的参与者比例相当。
  • V114对13个共有血清型达到非劣效标准,依据为幼儿加强免疫后30天血清型特异性IgG ≥0.35 μg/mL的参与者比例差值的双侧95%CI下限 >-10.0,以及IgG几何平均浓度(GMC)比值的双侧95%CI下限 >0.5。
  • V114对血清型22F和33F达到优效标准,依据为幼儿加强免疫后30天应答率的双侧95%CI下限 >10.0,以及IgG GMC比值的双侧95%CI下限 >2.0。
  • 对DTaP-IPV-Hib-HepB的抗体应答达到非劣效标准,依据为抗原特异性应答率。

关键数值与推荐

  • 非劣效标准:共有血清型IgG ≥0.35 μg/mL比例差值的双侧95%CI下限 >-10.0,IgG GMC比值双侧95%CI下限 >0.5。
  • 优效标准:血清型22F和33F应答率双侧95%CI下限 >10.0,IgG GMC比值双侧95%CI下限 >2.0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F. METHODS: Healthy infants were randomized to two primary doses and one toddler dose (2+1 regimen) of V114 or PCV13 at 3, 5, and 12 months of age; diphtheria, tetanus, pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib), hepatitis B (HepB) vaccine was administered concomitantly. Adverse events (AEs) were collected on Days 1-14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series, immediately prior to toddler dose, and 30 days post-toddler dose. Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for serotypes 22F and 33F. RESULTS: 1191 healthy infants were randomized to V114 (n = 595) or PCV13 (n = 596). Proportions of participants with solicited AEs and serious AEs were comparable between groups. V114 met non-inferiority criteria for 13 shared serotypes, based on difference in proportions with serotype-specific IgG ≥0.35 μg/mL (lower bound of two-sided 95% confidence interval [CI] >-10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5) at 30 days post-toddler dose. V114 met superiority criteria for serotypes 22F and 33F, based on response rates (lower bound of two-sided 95% CI >10.0) and IgG GMC ratios (lower bound of two-sided 95% CI >2.0) at 30 days post-toddler dose. Antibody responses to DTaP-IPV-Hib-HepB met non-inferiority criteria, based on antigen-specific response rates. CONCLUSION: A two-dose primary series plus toddler dose of V114 was well-tolerated in healthy infants. Compared with PCV13, V114 provided non-inferior immune responses to 13 shared serotypes and superior immune responses to additional serotypes 22F and 33F.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Benfield T, Rämet M, Valentini P, et al. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2). Vaccine. 2023. PMID: 36841723. doi:10.1016/j.vaccine.2023.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。